Molecular docking simulations suggest the oral GLP-1 weight loss drug danuglipron has higher binding affinity for CB1 and CB2 cannabinoid receptors than THC or the body's own endocannabinoids.
Pharmacology researchers; people using GLP-1 medications and cannabis; drug interaction specialists
Danuglipron bound CB1 and CB2 more strongly than THC in molecular docking
What the researchers found
Danuglipron showed higher binding affinity for both CB1 and CB2 receptors than THC, anandamide, or 2-AG in computational docking experiments, suggesting potential cross-reactivity between GLP-1 receptor agonists and the endocannabinoid system.
Why it matters
Millions of people use GLP-1 drugs for weight loss, and millions use cannabis. If GLP-1 drugs interact with cannabinoid receptors, there could be unexpected effects or drug interactions that clinicians should know about.
The numbers in context
Danuglipron had higher binding affinity for CB1 and CB2 than any tested endogenous (2-AG, anandamide) or exogenous (THC) cannabinoid receptor ligand.
How the study worked
Computational molecular docking experiments comparing binding affinities of danuglipron, THC, anandamide, and 2-AG at GLP-1R, CB1, and CB2 receptors.
What this study cannot tell us
Computational docking study only; binding affinity in silico does not prove functional activity in living systems. No in vitro or in vivo validation. Danuglipron is an oral GLP-1 agonist not yet widely available.
How to read the evidence
Computational docking study without experimental validation; preliminary until confirmed in vitro and in vivo.
When this study was published
2025 computational study
The bigger picture
The GLP-1 and endocannabinoid systems both regulate appetite and reward. This computational study suggests they may share molecular targets, opening questions about whether GLP-1 drugs partially work through the endocannabinoid system.
Questions still open
- Does danuglipron actually activate or block cannabinoid receptors in living cells? Could GLP-1 drug side effects (appetite changes, mood effects) partly involve the endocannabinoid system? Should cannabis users on GLP-1 drugs be monitored for interactions?
Common questions
Does this mean weight loss drugs affect the same system as cannabis?
Should people using GLP-1 drugs avoid cannabis?
Read the original research
Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.
microPublication biology, 2025
Citation
Dailey, Kiersten A; Schneider, Lillian N; Petreaca, Ruben C; Yoder, Ryan J. (2025). Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.. microPublication biology, 2025. https://doi.org/10.17912/micropub.biology.001690
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)